(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016619 A1

(51) International Patent Classification[7]: C07D 493/04, 209/34, A61K 31/40, A61P 31/18

(21) International Application Number: PCT/EP2003/050379

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02078384.1 14 August 2002 (14.08.2002) EP

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Unit 4, Block 4B, Blanchardstown Corporate Park, Blanchardstown, 15 Dublin (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TAHRI, Abdellah** [MA/BE]; Rue Maurice Albert Raskin, 30, B-1070 Anderlecht (BE). **WIGERINCK, Piet, Tom, Bert, Paul** [BE/BE]; Kardinaal Cardijnstraat 29, B-2840 Terhagen (BE).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L11 B3, B-2800 Mechelen (BE).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

[Continued on next page]

(54) Title: BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE HIV PROTEASE INHIBITORS



(I)



(II) (III) (IV)

(57) Abstract: The present invention concerns the compounds having the formula (I) *N*-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R_1 and R_8 each are H, optionally substituted C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-7}cycloalkyl, aryl, Het^1, Het^2; R_1 may also be a radical of formula $(R_{11a}R_{11b})NC(R_{10a}R_{10b})CR_9$-; t is 0, 1 or 2; R_2 is H or C_{1-6}alkyl; L is -C(=O)-, -O-C(=O)-, -NR_8-C(=O)-, -O-C_{1-6} alkanediyl-C(=O)-, -NR_8-C_{1-6}alkanediyl-C(=O)-, -S(=O)$_2$-, -O-S(=O)$_2$-, -NR_8-S(=0)$_2$; R_3 is C_{1-6}alkyl, aryl, C_{3-7} cycloalkyl, C_{3-7}cycloalkylC_{1-4} alkyl, or arylC_{1-4}alkyl; R_4 is H, C_{1-4}alkylOC(=O), carboxyl, aminoC(=O), mono- or di(C_{1-4}alkyl)aminoC(=O), C_{3-7}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl or optionally substituted C_{1-6}alkyl; formula (II) is formula (III) or formula (IV) ; R_{5a} and R_{5b} is C_{2-6}alkenyl, C_{2-6} alkynyl, C_{3-7}cycloalkyl or C_{1-6}alkyl, optionally substituted on one or more atoms; R_{5a} and R_{5b} may also be hydrogen, aryl, Het^1, Het^2; R_6 is hydrogen or C_{1-6}alkyl optionally substituted on one ore more carbon atoms. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.

WO 2004/016619 A1

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.